FINWIRES · TerminalLIVE
FINWIRES

$VRTX

12 stories mentioning VRTXUpdated just now

Every FINWIRES story that references VRTX, newest first.

Insider Trading

Vertex Pharmaceuticals Insider Sold Shares Worth $1,827,900, According to a Recent SEC Filing

Carmen Bozic, Chief Medical Officer and Executive Vice President, on June 15, 2026, sold 4,062 shares in Vertex Pharmaceuticals (VRTX) for $1,827,900. Following the Form 4 filing with the SEC, Bozic has control over a total of 16,953 common shares of the company, with 16,953 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/875320/000087532026000235/xslF345X05/wk-form4_1781727153.xml

$VRTX
Insider Trading

Vertex Pharmaceuticals Insider Sold Shares Worth $785,250, According to a Recent SEC Filing

Carmen Bozic, Chief Medical Officer and Executive Vice President, on June 05, 2026, sold 1,745 shares in Vertex Pharmaceuticals (VRTX) for $785,250. Following the Form 4 filing with the SEC, Bozic has control over a total of 21,015 common shares of the company, with 21,015 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/875320/000087532026000233/xslF345X05/wk-form4_1781036661.xml

$VRTX
Insider Trading

Vertex Pharmaceuticals Insider Sold Shares Worth $888,300, According to a Recent SEC Filing

Carmen Bozic, Executive Vice President and Chief Medical Officer, on May 29, 2026, sold 1,974 shares in Vertex Pharmaceuticals (VRTX) for $888,300. Following the Form 4 filing with the SEC, Bozic has control over a total of 22,760 common shares of the company, with 22,760 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/875320/000087532026000228/xslF345X05/wk-form4_1780430661.xml

$VRTX
Wire

Vertex Says Health Canada Accepts Suzetrigine Application for Review

Vertex Pharmaceuticals (VRTX) said Thursday that Health Canada accepted for review its new drug submission for suzetrigine for the treatment of moderate-to-severe acute pain in adults.Suzetrigine is an investigational, oral, selective NaV1.8 pain signal inhibitor and represents a new class of oral pain medicine that is neither an opioid nor a nonsteroidal anti-inflammatory drug, the company said.The company added that it intends for the regulatory review of suzetrigine to be part of an aligned review with Canadian Health Technology Assessment Organizations, including Canada's Drug Agency and Quebec's Institut national d'excellence en sante et en services sociaux.Suzetrigine was approved by the US Food and Drug Administration under the brand name Journavx in January 2025 and received breakthrough therapy, fast track and priority review designations, the biotechnology company said.Price: $432.66, Change: $+2.22, Percent Change: +0.52%

$VRTX
Insider Trading

Vertex Pharmaceuticals Insider Sold Shares Worth $613,971, According to a Recent SEC Filing

Carmen Bozic, Chief Medical Officer and Executive Vice President, on May 15, 2026, sold 1,354 shares in Vertex Pharmaceuticals (VRTX) for $613,971. Following the Form 4 filing with the SEC, Bozic has control over a total of 24,734 common shares of the company, with 24,734 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/875320/000087532026000225/xslF345X05/wk-form4_1779221059.xml

$VRTX
Insider Trading

Vertex Pharmaceuticals Insider Sold Shares Worth $469,222, According to a Recent SEC Filing

Joy Liu, Executive Vice President and Chief Legal Officer, on May 01, 2026, sold 1,104 shares in Vertex Pharmaceuticals (VRTX) for $469,222. Following the Form 4 filing with the SEC, Liu has control over a total of 20,729 common shares of the company, with 20,729 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/875320/000087532026000183/xslF345X05/wk-form4_1778015480.xml

$VRTX
Wire

Vertex Pharmaceuticals Confident in Emerging Renal Franchise, Oppenheimer Says

Vertex Pharmaceuticals' (VRTX) management remains confident in its emerging renal franchise, suggesting it could rival or even exceed its cystic fibrosis franchise eventually, Oppenheimer said in a Tuesday note.The strong uptake of Alyftrek is encouraging, and Oppenheimer expects continued growth in US and international markets, driven by adoption among treatment-naive patients, those who previously discontinued cystic fibrosis therapy, and patients who switched to Alyftrek, according to the note.Uptake of Alyftrek among younger patients and more access in Europe should support long-term growth, according to the note. For Journavx, management remains confident in tripling total scripts in 2026, the brokerage said.Management remains confident in Pove's profile, and the recent submission completion for Pove suggests a potential FDA decision by year-end, according to the note.Oppenheimer said Inaxaplin represents the next key catalyst, with the phase 2 AMPLIFIED study readout now expected in H2, compared with the prior mid-2026 guidance.Oppenheimer maintained an outperform rating on Vertex Pharmaceuticals with a price target of $600.Price: $423.92, Change: $-5.93, Percent Change: -1.38%

$VRTX
Asia Markets

US Equity Futures Gain Pre-Bell as Traders Keep Eye on Potential Re-Escalation of Middle East Hostilities

US equity futures were higher pre-bell Tuesday as traders kept a close watch on the potential re-escalation of hostilities in the Middle East.Dow Jones Industrial Average futures were 0.4% higher, S&P 500 futures were up 0.5%, and Nasdaq futures were 0.8% higher.The UAE said that it was attacked by Iranian drones and missiles, while the US said it sank Iranian boats in the Strait of Hormuz.President Donald Trump had said that the US would help guide vessels stranded in the Persian Gulf. In a post Monday on Truth Social, he said that a South Korean cargo ship had been damaged by Iran, but the US had shot down seven Iranian small boats."Other than the South Korean Ship, there has been, at this moment, no damage going through the Strait," Trump said.Traders digested the latest round of earnings, with Palantir Technologies (PLTR) and Vertex Pharmaceuticals (VRTX) reporting higher Q1 adjusted earnings and revenue. HSBC (HSBC) also posted an increase in Q1 earnings and revenue.Oil prices were lower, with front-month global benchmark North Sea Brent crude down 2.2% at $111.91 per barrel and US West Texas Intermediate crude 3.2% lower at $103.04 per barrel.The US international trade deficit widened to $60.31 billion in March from a $57.78 billion gap in February, compared with a $61.0 billion gap expected in a survey compiled by Bloomberg as of 7:40 am ET.The S&P Global purchasing managers' index composite final report for April, due at 9:45 am ET, is seen reporting 52.1 versus 52.0 previously.March new home sales report, due at 10 am ET, is expected to post a 652,000 annual rate. The April Institute for Supply Management's services index is projected at 53.7 versus 54.0 previously. March job openings from the US Department of Labor's Job Openings and Labor Turnover Survey are expected to come in at 6.850 million compared with 6.882 million in the prior month.Federal Reserve Vice Chair for Supervision Michelle Bowman and Fed Governor Michael Barr are due to speak today.In other world markets, Japan's Nikkei and China's Shanghai Composite were closed due to public holidays. Hong Kong's Hang Seng ended 0.8% lower. The UK's FTSE 100 was down 1.4%, and Germany's DAX index was 1.6% higher in Europe's early afternoon session.In equities, Intel (INTC) shares were up 3.8% after Bloomberg reported the Apple (AAPL) has held early discussions with the company and Samsung Electronics on producing key device processors in the US. Anheuser-Busch InBev (BUD) stock was up 6.6% after the company reported fiscal Q1 underlying earnings and revenue that beat analysts' estimates. Pinterest (PINS) shares were up 18% after the company posted higher Q1 non-GAAP earnings and revenue that beat analysts' consensus.On the losing side, Palantir and HSBC shares were down 1.3% and 3.9%, respectively, after they reported Q1 financial results. Shopify (SHOP) stock was 5.9% lower after the company reported a Q1 loss while analysts expected earnings.

Dow JonesNasdaq CompositeS&P 500$AAPL$BUD$HSBC$INTC$PINS$PLTR$SHOP$VRTX
Japan

US Equity Futures Higher Pre-Bell as Traders Keep Eye on Potential Re-Escalation of Middle East Hostilities

US equity futures were higher pre-bell Tuesday as traders kept a close watch on the potential re-escalation of hostilities in the Middle East.Dow Jones Industrial Average futures were 0.3% higher, S&P 500 futures were up 0.4%, and Nasdaq futures were 0.6% higher.The UAE said that it was attacked by Iranian drones and missiles, while the US said it sank Iranian boats in the Strait of Hormuz.President Donald Trump had said that the US would help guide vessels stranded in the Persian Gulf. In a post Monday on Truth Social, he said that a South Korean cargo ship had been damaged by Iran, but the US had shot down seven Iranian small boats."Other than the South Korean Ship, there has been, at this moment, no damage going through the Strait," Trump said.Traders digested the latest round of earnings, with Palantir Technologies (PLTR) and Vertex Pharmaceuticals (VRTX) reporting higher Q1 adjusted earnings and revenue. HSBC (HSBC) also posted a Q1 increase in earnings and revenue.Oil prices were lower, with front-month global benchmark North Sea Brent crude down 1.6% at $112.67 per barrel and US West Texas Intermediate crude 2.4% lower at $103.94 per barrel.The international trade in goods report, scheduled for release at 8:30 am ET, is expected to post a deficit widening to $61 billion from $57.3 billion in the prior month, according to estimates compiled by Bloomberg. The purchasing managers' index composite final report for April, due at 9:45 am ET, i is seen coming in at 52.1 versus 52.0 previously.March new home sales, due at 10 am ET, is seen coming in at a 652,000 annual rate. The April Institute for Supply Management's services index is projected at 53.7 versus 54.0 previously. March job openings from the Department of Labor's Job Openings and Labor Turnover Survey are expected to come in at 6.850 million compared with 6.882 million in the prior month.Federal Reserve Vice Chair for Supervision Michelle Bowman is slated to speak at 10 am, while Fed Governor Michael Barr speaks at 12:30 pm.

Dow JonesNasdaq CompositeS&P 500$HSBC$PLTR$VRTX
Research

Research Alert: CFRA Retains Buy Rating On Shares Of Vertex Pharmaceuticals Incorporated

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After Q1 results, we lower our target price to $535 from $579, 24.4x our 2027 EPS, a discount to VRTX's 10-year historical forward P/E average. We maintain our 2026 EPS view of $19.40 and our 2027 EPS estimate at $21.92. VRTX's Q1 2026 was marked by robust revenue growth, successful commercial execution of new products, and significant progress in its clinical pipeline, particularly in the renal space. The company's CF franchise remains the primary revenue driver, while new products like Casgevy and Gernavics are beginning to contribute meaningfully to growth, accounting for approximately 25% of the total product revenue growth in Q1. Pipeline advancement remains robust, in our view, with the completion of the rolling BLA submission for povetacicept in IgA nephropathy representing a significant regulatory milestone. Using a Priority Review Voucher, VRTX expects an expedited six-month FDA review timeline, which is encouraging.

$VRTX
Research

Research Alert: Vertex Reports Mixed Q1, Reaffirms Full-year 2026 Financial Guidance

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Vertex delivered mixed Q1 results with revenue of $2.99B (+8% Y/Y) falling $10M short of expectations, though non-GAAP EPS of $4.47 (+10% Y/Y) beat the consensus by $0.16. The quarter demonstrated successful execution of VRTX's multi-product launch strategy, with ALYFTREK generating $424.4M (vs. $53.9M prior year), CASGEVY contributing $42.9M (+202% Y/Y), and JOURNAVX adding $29.0M in its second commercialization year. Recent FDA label extensions for ALYFTREK and TRIKAFTA expanded CF patient eligibility to ~95% in the U.S., adding roughly 800 more patients. VRTX maintained its 2026 guidance unchanged with total revenue expectations of $12.95B-$13.1B and non-CF product revenue of $500M or greater. We view the operating leverage positively, with revenue growth outpacing expense increases, and believe the diversification strategy beyond CF continues to gain traction with meaningful contributions from newly launched therapies across multiple therapeutic areas.

$VRTX
Wire

GUIDANCE: (VRTX) Vertex Pharmaceuticals Expects 2026 Revenue Range $12.95B-$13.1B, vs. FactSet Est of $13.05B

GUIDANCE: (VRTX) Vertex Pharmaceuticals Expects 2026 Revenue Range $12.95B-$13.1B, vs. FactSet Est of $13.05B

$VRTX

Track with the FINWIRES app suite